Licensing deals

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

Leo's eczema prospect hits primary endpoint in phase 2b

Leo shared phase 2b data on temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.
Nick Paul Taylor May 9, 2025 7:30am
ship offload depart tugboat boat

Neurocrine hands back 2 CNS gene therapy programs to Voyager

May 7, 2025 7:30am
MA strategy deal block push come together form

Amicus pays Dimerix $30M for late-phase rare kidney disease drug

May 1, 2025 10:59am
euro money cash coins Europe

Ferrer nabs European rights for ALS asset in €500M pact

Apr 28, 2025 2:40pm
Mosaic pattern collage

Mosaic licenses 2 clinical stage tumor drugs from Otsuka's Astex

Apr 24, 2025 10:00am
Glowing puzzle piece fitting into puzzle

Boehringer slots synthetic lethal program into oncology pipeline

Apr 23, 2025 7:45am